TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs

Protara Therapeutics, Inc.

BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.
BCG-Naïve cohort: CR rate 66.7% at 6 months (18/27), 57.9% at 12 months (11/19); 66.7% re-induction conversion.
No Grade 3 or greater treatment-related adverse events; no discontinuations due to TRAEs; common TRAEs were dysuria (14%), bladder spasm (9%).
Enrollment completion of BCG-Unresponsive registrational cohort expected 2H 2026; ADVANCED-3 registrational trial for BCG-Naïve to start 2H 2026.
Data presented at ASCO GU 2026; company hosted conference call on Feb 24, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.